Pre-treatment blood levels of cell-free DNA fragments longer than 1650 base pairs predict early progression and progression-free survival in advanced cancer patients treated with immune checkpoint inhibitors.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
fields
q-bio.QM 1years
2025 1verdicts
CONDITIONAL 1representative citing papers
citing papers explorer
-
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors
Pre-treatment blood levels of cell-free DNA fragments longer than 1650 base pairs predict early progression and progression-free survival in advanced cancer patients treated with immune checkpoint inhibitors.